GHK-Cu Injection Dosage Per Day: The Step-By-Step Protocol Beginners Get Wrong

Most people researching GHK-Cu skip straight to a number, "just tell me how many milligrams", and end up copying a dose meant for a 200-pound man onto a 130-pound frame. That's the fastest way to waste a vial and get skin irritation for nothing.

Important: We're not doctors. This article breaks down what published research and documented protocols say about GHK-Cu dosing, it is not medical advice. Talk to a qualified healthcare provider before starting any peptide protocol.

Note: GHK-Cu is classified as a research compound. It is not FDA-approved for injection in humans (it does appear in FDA-regulated topical cosmetic formulations at much lower concentrations). Everything below is based on published lab research, wound-healing studies, and documented research protocols, not a recommendation to self-administer.

This is for people who have already decided, after talking to a clinician, to research GHK-Cu dosing structure. It is not for anyone pregnant, anyone with Wilson's disease or another copper-metabolism disorder, anyone with an active malignancy, or anyone hoping to skip the "ask a doctor" step.

The Short Version (Read This First)

• Typical researched dose range: 1–2 mg per day, subcutaneously, for most adults; some studies scale up to 3 mg for larger body weights.
• Cycle length: 3–4 weeks "on," then 2–4 weeks off. Continuous, uncycled use is the most common mistake.
• Timing: Once daily, same time each day. Consistency matters more than morning-vs-night.
• Site rotation: Never the same spot two days in a row (more on this below).
• Biggest red flag: A metallic taste that doesn't fade, chest tightness, or a headache that gets worse instead of better, stop and call a clinician.

What Is GHK-Cu, and Why Does the Dose Matter So Much?

GHK-Cu is a naturally occurring copper-binding peptide the body already makes, but production drops sharply with age, from about 200 ng/mL in young adults down to roughly 80 ng/mL by age 60, according to research from Loren Pickart's lab, one of the first teams to characterize the peptide's role in tissue repair (Pickart et al., 2018).

That drop-off is the whole reason people research it: less native GHK-Cu is linked to slower wound healing and thinner skin in lab studies. But copper is also a mineral your body tightly regulates. Too little does nothing; too much builds up and can cause its own problems. That's why dose and cycle length matter more here than with almost any other research peptide.

Step-By-Step: How to Approach GHK-Cu Dosing

Step 1: Get medical clearance first

Copper accumulates in the liver. Anyone with liver disease, Wilson's disease, or a history of copper sensitivity should not be researching injectable copper peptides without a doctor's input. This step isn't optional, it's step one for a reason.

Step 2: Calculate the dose by body weight, not by guesswork

Most documented research protocols land between 1 mg and 2 mg per day for an average adult, occasionally up to 3 mg for larger body weights. Weigh the peptide, don't eyeball the syringe. If you're unsure how to convert a vial's total mg into a daily draw, a peptide dosage calculator walks through the math step by step.

Step 3: Reconstitute correctly before you draw anything

GHK-Cu comes as a lyophilized (freeze-dried) powder that has to be mixed with bacteriostatic water before injection. Get this ratio wrong and every dose after it is wrong too. See our guides on how to reconstitute peptides and choosing the right bacteriostatic water before opening the vial.

Step 4: Pick your injection site, and plan to rotate it

Subcutaneous injection (into the fat layer, not the muscle) is the standard route in documented protocols. The abdomen, thigh, and upper glute are the most common sites. Rotating matters because repeated injections in the same spot cause local tissue irritation and, over time, visible lumps or scar tissue. Our injection site rotation guide lays out a simple weekly pattern.

Step 5: Inject at the same time every day

The exact hour doesn't seem to matter much in the available research, morning and evening dosing show similar patterns in small studies, but consistency does. A dose taken at 8 a.m. one day and 9 p.m. the next makes it harder to track side effects and harder to know if the protocol is even working.

Step 6: Cycle it, don't run it year-round

This is the step most beginners skip, and it's the one that matters most. Because copper builds up in tissue, most documented research protocols use a 3-to-4-week "on" period followed by a 2-to-4-week break. Running GHK-Cu continuously for months without a break isn't how it's been studied, and it removes any safety margin built into the dosing.

Step 7: Track what you notice, and adjust conservatively

Keep a simple log: dose, site, time, and anything you notice (skin changes, taste in your mouth, energy, sleep). If nothing changes after a full cycle, the answer is not automatically "take more." Copper peptides don't follow a "more is better" curve, overshooting the dose is more likely to cause irritation than extra benefit.

The Mistakes That Ruin a GHK-Cu Protocol

Mistake #1: Copying someone else's dose. A protocol built for a 220-pound bodybuilder posted in a forum is not automatically safe for a 140-pound beginner. Scale to your own body weight, not to whoever posted the loudest results online.

Mistake #2: Never cycling off. Continuous daily use for months at a time isn't how GHK-Cu has been studied, and it's the fastest way to build up more copper than your body is used to clearing.

Mistake #3: Injecting the same spot every day. This is the number-one cause of the small, hard lumps people report under the skin after a few weeks. Rotate the site every single time.

Mistake #4: Ignoring total copper intake. If you're also taking a copper supplement, using copper-based skincare, or eating a diet already high in shellfish, organ meats, or nuts, your total copper load is higher than the injection dose alone suggests. Account for all sources, not just the syringe.

Mistake #5: Skipping the purity check. Research peptides vary wildly in quality between suppliers. A certificate of analysis tells you what's actually in the vial, and whether it's actually GHK-Cu at the concentration the label claims. If a vendor won't provide one, that's a red flag, not a minor inconvenience.

Mistake #6: Storing it wrong. Reconstituted GHK-Cu needs refrigeration and has a limited shelf life once mixed. Leaving it at room temperature or in a hot car degrades the peptide before it ever reaches your skin. See how to store peptides properly for the specifics.

Where Does the "1–2 mg" Number Actually Come From?

Most of the human dosing data on GHK-Cu comes from topical and wound-care research rather than large injectable trials, which is worth being honest about. Early lab work by Maquart and colleagues found that GHK-Cu stimulated collagen production in fibroblast cultures at very low concentrations, which is part of why researchers became interested in copper peptides for skin and tissue repair in the first place (Maquart et al., 1988).

Later reviews summarizing decades of GHK-Cu research describe its role in stimulating collagen, activating antioxidant enzymes, and supporting tissue remodeling across multiple cell types, but most of that evidence comes from cell cultures and animal models, not large-scale human injection trials (Pickart, Vasquez-Soltero & Margolina, 2015). That gap is exactly why a conservative, cycled, body-weight-scaled dose, rather than an aggressive one, is the approach most documented protocols take.

If your interest in GHK-Cu is mainly about skin appearance rather than injection, it's worth comparing the injectable route against topical use before committing to needles at all, our before-and-after protocol breakdown covers that decision in more detail, and our skin and tissue repair overview covers what the research says about mechanism.

Red Flags: When to Stop and Call a Clinician

Stop the protocol and contact a healthcare provider if you notice any of the following:

• A metallic taste that persists for hours or gets stronger over time
• Chest tightness, heart palpitations, or shortness of breath
• A headache that worsens instead of improving over a few days
• Redness, warmth, or swelling at an injection site that doesn't fade within 48 hours
• Nausea, vomiting, or yellowing of the skin or eyes (possible signs of liver stress from copper buildup)
• Any known liver condition or history of Wilson's disease that wasn't disclosed before starting

None of these symptoms are things to "push through." Copper accumulation is cumulative and slow to reverse, so catching a problem early matters more here than with most other research peptides.

The One-Sentence Version

Scale the dose to your body weight, cycle it in 3-to-4-week blocks with real breaks in between, rotate your injection sites, and treat any metallic taste or chest symptom as a stop sign, not a side effect to wait out.

If you're building out a broader research routine, it's also worth reading up on peptide stacking basics and general peptide cycling strategy before combining GHK-Cu with anything else.

---

Medical Disclaimer: The information on this website is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide protocol, medication, or supplement regimen. Individual results vary. This article shares published research and documented protocols, not medical recommendations.

Sources

1. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data, International Journal of Molecular Sciences, 2018
2. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration, BioMed Research International, 2015
3. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+, FEBS Letters, 1988
4. The Human Tripeptide GHK-Cu in Prevention of Oxidative Stress and Degenerative Conditions of Skin, Oxidative Medicine and Cellular Longevity, 2012